… had a neutral effect on cardiovascular outcomes.10, 11 In … kidney disease and of insulin
glargine, in people with and without early chronic kidney disease, on cardiovascular outcomes in …

… of tirzepatide and insulin glargine on kidney parameters and outcomes in people … of kidney
outcomes, with a low risk of clinically relevant hypoglycaemia, compared with insulin glargine …

… Studies including prespecified kidney outcome data were identified. Composite kidney
outcomes were reported in a prespecified analysis of the LEADER cardiovascular outcome trial, …

… with the composite kidney outcome in participants with … kidney outcome in participants
with baseline microalbuminuria. (C) Proportion of participants with the composite outcome in …

… Allocation to the insulin glargine group reduced the incidence of the primary microvascular
composite outcome of kidney and eye disease in participants whose baseline HbA 1c level …

… Our results found that insulin glargine U100 could be effective, … episodes compared with
NPH insulin in this population. These … outcomes of insulin glargine with NPH insulin, premixed …

… renal function, or on drugs that may adversely affect renal … short-acting regular human insulin,
received insulin glargine as the … In the outcome reduction with initial glargine intervention (…

… , the sulfonylurea glimepiride, the GLP-1 receptor agonist liraglutide, and the basal insulin
glargine. As noted, DPP-4 inhibitors and GLP-1 receptor agonists have shown modest …

… controlled in DCCT, sustained reductions in nephropathy, neuropathy, and retinopathy
were observed, in addition to reductions in severe retinal and renal outcomes. Citation57 …

… the safety and efficacy of insulin glargine in type 2 diabetic … the safety and efficacy of insulin
glargine in type 2 diabetic … (OAD) or NPH insulin received insulin glargine at bedtime. The …